CDK
CDK(细胞周期蛋白依赖性激酶)
CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.
There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.
CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).
CDK 相关产品(269)
- GC50615BSJ-03-204CAS: 2349356-09-6纯度: >98.00%
BSJ-03-204 是一种 PROTAC,由 Cereblon 和 CDK 的配体连接。 BSJ-03-204 是一种有效且选择性的基于 Palbociclib 的 CDK4/6 双降解剂 (PROTAC),对 CDK4/D1 和 CDK6/D1 的 IC50 分别为 26.9 nM 和 10.4 nM。 BSJ-03-204 不诱导 IKZF1/3 降解并具有抗癌活性。
- GC50719FMF-04-159-RCAS: 2741262-15-5纯度: >98.00%
Potent inhibitor of CDK16 and CDK14 (IC50 values are 6 and 140 nM, respectively in kinase activity assay; IC50 = 563 nM for CDK14 in BRET assay)
- GC60324Ribociclib D6CAS: 1328934-40-2
RibociclibD6(LEE011D6)是Ribociclib的一种氘代化合物。Ribociclib是一种高度特异性的CDK4/6抑制剂,IC50值分别为10nM和39nM,对cyclinB/CDK1复合体的活性低于其1000倍。
- GC605326-(Dimethylamino)purineCAS: 938-55-6纯度: >98.00%
6-Dimethylaminopurine (N,N-Dimethyladenine) is a serine threonine protein kinase inhibitor. It inhibits the germinal vesicle breakdown and the meiotic maturation of oocytes.
- GC60680CDK5 inhibitor 20-223CAS: 865317-30-2纯度: >99.50%
CDK5inhibitor20-223是一种有效的CDK2和CDK5抑制剂,IC50分别为6.0和8.8nM。CDK5inhibitor20-223有潜力用于结肠直肠癌(CRC)的研究。
- GC61008LSN3106729 hydrochloride纯度: >99.00%
LSN3106729hydrochloride,Abemaciclib的代谢物,是一种具有抗肿瘤活性的CDK抑制剂。LSN3106729hydrochloride和CRBN配体可用于设计PROTACCDK4/6降解剂。
- GC61925hSMG-1 inhibitor 11jCAS: 1402452-15-6纯度: >98.00%
hSMG-1 inhibitor 11j是一种嘧啶衍生物,是一种强效且选择性的hSMG-1抑制剂,IC 50 值为0.11nM。
- GC62112ZotiraciclibCAS: 1204918-72-8纯度: >99.00%
Zotiraciclib (SB1317; TG02) is a novel small molecule potent CDK/JAK2/FLT3 inhibitor, emerged with potent CDK (IC50 against CDKs 1, 2 and 9 = 9, 5 and 3 nM, respectively), FLT3 (IC50 = 19 nM) and JAK2 (IC50 = 19 nM) potency.
- GC62319Samuraciclib trihydrochloride纯度: >99.00%
Samuraciclib (CT7001) trihydrochloride 是一种有效的,具有选择性,ATP 竞争性和口服活性的 CDK7 抑制剂,IC50 为 41 nM。Samuraciclib trihydrochloride 对 CDK7 的选择性分别是 CDK1,CDK2 (IC50 为 578 nM),CDK5 和 CDK9 的 45 倍,15 倍,230 倍和 30 倍。Samuraciclib trihydrochloride 以 GI50 值为 0.2-0.3 µM 来抑制乳腺癌细胞系的生长,具有有效的抗肿瘤作用。
- GC62392KB-0742 dihydrochlorideCAS: 2416874-75-2纯度: >99.50%
KB-0742 Dihydrochloride is a potent, selective, and orally bioavailable small molecule inhibitor of the transcription elongation cofactor CDK9 with IC50 of 6 nM for CDK9/cyclin T1 inhibition at 10 μM ATP.
- GC62423GSK-3/CDK5/CDK2-IN-1CAS: 395074-72-3纯度: >98.50%
GSK-3/CDK5/CDK2-IN-1,一种咪唑衍生物,是 cdk5,cdk2 和 GSK-3 的抑制剂。GSK-3/CDK5/CDK2-IN-1 可用于癌症和神经退行性疾病的研究。详细信息请参考专利文献 WO2002010141A1 中的化合物 9a。
- GC62442Casein Kinase inhibitor A51CAS: 2079068-74-7纯度: >98.00%
Casein Kinase inhibitor A51 是一种有效且具有口服活性的酪蛋白激酶 1α (CK1α) 抑制剂。Casein Kinase inhibitor A51 可诱导白血病细胞凋亡 (apoptosis),并具有有效的抗白血病活性。
- GC62572hSMG-1 inhibitor 11eCAS: 1402452-10-1纯度: >99.00%
hSMG-1 inhibitor 11e 是一种有效的选择性的 hSMG-1 激酶抑制剂,其 IC50 值 <0.05 nM。hSMG-1 inhibitor 11e 对 hSMG-1 的选择性比 mTOR (IC50 为 45 nM),PI3Kα/γ (IC50 为 61 nM 和 92 nM) 和 CDK1/CDK2 (IC50 为 32 μM 和 7.1 μM) 高 900 倍。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC50239 | ML 315 hydrochloride | 1440251-53-5 | - | |
Inhibitor of Clk and DYRK kinases | ||||
| GC50452 | BRD 6989 | 642008-81-9 | >99.50% | |
A Cdk8/cyclin C complex inhibitor | ||||
| GC50484 | TL 12-186 | 2250025-88-6 | >98.00% | |
TL 12-186 是一种依赖于大脑的多激酶 PROTAC 降解剂。多激酶包括 CDK、BTK、FLT3、Aurora 激酶、TEC、ULK、ITK 等。 TL 12-186 抑制 CDK2/cyclin A (IC50\u003d73 nM) 和 CDK9/cyclin T1 (IC50\u003d55 nM)。 | ||||
| GC50532 | KuWal151 | 2341841-06-1 | - | |
Potent and selective CLK inhibitor | ||||
| GC50615 | BSJ-03-204 | 2349356-09-6 | >98.00% | |
BSJ-03-204 是一种 PROTAC,由 Cereblon 和 CDK 的配体连接。 BSJ-03-204 是一种有效且选择性的基于 Palbociclib 的 CDK4/6 双降解剂 (PROTAC),对 CDK4/D1 和 CDK6/D1 的 IC50 分别为 26.9 nM 和 10.4 nM。 BSJ-03-204 不诱导 IKZF1/3 降解并具有抗癌活性。 | ||||
| GC50719 | FMF-04-159-R | 2741262-15-5 | >98.00% | |
Potent inhibitor of CDK16 and CDK14 (IC50 values are 6 and 140 nM, respectively in kinase activity assay; IC50 = 563 nM for CDK14 in BRET assay) | ||||
| GC60324 | Ribociclib D6 | 1328934-40-2 | - | |
RibociclibD6(LEE011D6)是Ribociclib的一种氘代化合物。Ribociclib是一种高度特异性的CDK4/6抑制剂,IC50值分别为10nM和39nM,对cyclinB/CDK1复合体的活性低于其1000倍。 | ||||
| GC60532 | 6-(Dimethylamino)purine | 938-55-6 | >98.00% | |
6-Dimethylaminopurine (N,N-Dimethyladenine) is a serine threonine protein kinase inhibitor. It inhibits the germinal vesicle breakdown and the meiotic maturation of oocytes. | ||||
| GC60680 | CDK5 inhibitor 20-223 | 865317-30-2 | >99.50% | |
CDK5inhibitor20-223是一种有效的CDK2和CDK5抑制剂,IC50分别为6.0和8.8nM。CDK5inhibitor20-223有潜力用于结肠直肠癌(CRC)的研究。 | ||||
| GC60681 | CDK7/9 tide | - | - | |
CDK7/9tide是CDK7或CDK9的肽底物。 | ||||
| GC61008 | LSN3106729 hydrochloride | - | >99.00% | |
LSN3106729hydrochloride,Abemaciclib的代谢物,是一种具有抗肿瘤活性的CDK抑制剂。LSN3106729hydrochloride和CRBN配体可用于设计PROTACCDK4/6降解剂。 | ||||
| GC61925 | hSMG-1 inhibitor 11j | 1402452-15-6 | >98.00% | |
hSMG-1 inhibitor 11j是一种嘧啶衍生物,是一种强效且选择性的hSMG-1抑制剂,IC 50 值为0.11nM。 | ||||
| GC62112 | Zotiraciclib | 1204918-72-8 | >99.00% | |
Zotiraciclib (SB1317; TG02) is a novel small molecule potent CDK/JAK2/FLT3 inhibitor, emerged with potent CDK (IC50 against CDKs 1, 2 and 9 = 9, 5 and 3 nM, respectively), FLT3 (IC50 = 19 nM) and JAK2 (IC50 = 19 nM) potency. | ||||
| GC62139 | XY028-140 | 2229974-83-6 | >98.00% | |
MS140 is a specific and highly potent CDK4/6 kinase inhibitor and also a CDK4/6 degrader (PROTAC). | ||||
| GC62168 | CDK-IN-6 | 779353-02-5 | >98.00% | |
CDK-IN-6,是一类吡唑并[1,5-a]嘧啶化合物,是一种具有抗癌活性的 CDK 抑制剂。 | ||||
| GC62263 | BSJ-4-116 | 2519823-34-6 | >99.50% | |
BSJ-4-116 is a specific degrader of cyclin-dependent kinase 12 (CDK12). BSJ-4-116 exhibits potent antiproliferative effects. | ||||
| GC62294 | YKL-5-124 | 1957203-01-8 | >98.00% | |
YKL-5-124 TFA是一种强效、选择性、不可逆的共价CDK7抑制剂,对CDK7和CDK7/Mat1/CycH复合物的IC 50 值分别为53.5nM和9.7nM。 | ||||
| GC62319 | Samuraciclib trihydrochloride | - | >99.00% | |
Samuraciclib (CT7001) trihydrochloride 是一种有效的,具有选择性,ATP 竞争性和口服活性的 CDK7 抑制剂,IC50 为 41 nM。Samuraciclib trihydrochloride 对 CDK7 的选择性分别是 CDK1,CDK2 (IC50 为 578 nM),CDK5 和 CDK9 的 45 倍,15 倍,230 倍和 30 倍。Samuraciclib trihydrochloride 以 GI50 值为 0.2-0.3 µM 来抑制乳腺癌细胞系的生长,具有有效的抗肿瘤作用。 | ||||
| GC62392 | KB-0742 dihydrochloride | 2416874-75-2 | >99.50% | |
KB-0742 Dihydrochloride is a potent, selective, and orally bioavailable small molecule inhibitor of the transcription elongation cofactor CDK9 with IC50 of 6 nM for CDK9/cyclin T1 inhibition at 10 μM ATP. | ||||
| GC62423 | GSK-3/CDK5/CDK2-IN-1 | 395074-72-3 | >98.50% | |
GSK-3/CDK5/CDK2-IN-1,一种咪唑衍生物,是 cdk5,cdk2 和 GSK-3 的抑制剂。GSK-3/CDK5/CDK2-IN-1 可用于癌症和神经退行性疾病的研究。详细信息请参考专利文献 WO2002010141A1 中的化合物 9a。 | ||||
| GC62427 | Cdc7-IN-5 | 1402057-86-6 | >95.00% | |
Cdc7-IN-5 (compound I-B) 是一种有效的 Cdc7 激酶抑制剂,详情请参考文献 WO2019165473A1,compound I-B。Cdc7 是一种丝氨酸苏氨酸蛋白激酶酶,在细胞周期中对 DNA 复制的启动至关重要。 | ||||
| GC62442 | Casein Kinase inhibitor A51 | 2079068-74-7 | >98.00% | |
Casein Kinase inhibitor A51 是一种有效且具有口服活性的酪蛋白激酶 1α (CK1α) 抑制剂。Casein Kinase inhibitor A51 可诱导白血病细胞凋亡 (apoptosis),并具有有效的抗白血病活性。 | ||||
| GC62572 | hSMG-1 inhibitor 11e | 1402452-10-1 | >99.00% | |
hSMG-1 inhibitor 11e 是一种有效的选择性的 hSMG-1 激酶抑制剂,其 IC50 值 <0.05 nM。hSMG-1 inhibitor 11e 对 hSMG-1 的选择性比 mTOR (IC50 为 45 nM),PI3Kα/γ (IC50 为 61 nM 和 92 nM) 和 CDK1/CDK2 (IC50 为 32 μM 和 7.1 μM) 高 900 倍。 | ||||
| GC62596 | CDK7-IN-3 | 2417302-07-7 | >99.50% | |
CDK7-IN-3 (CDK7-IN-3) 是一种具有口服活性的高选择性非共价 CDK7 抑制剂,KD 为 0.065 nM。 CDK7-IN-3 对 CDK2 (Ki=2600 nM)、CDK9 (Ki=960 nM)、CDK12 (Ki=870 nM) 显示出较差的抑制作用。 CDK7-IN-3 诱导肿瘤细胞凋亡并具有抗肿瘤活性。 | ||||
